
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional advisers.

If you have sold or transferred all your shares in Arta TechFin Corporation Limited, you should at once hand this circular with the accompanying form of proxy to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected, for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



ARTA TECHFIN CORPORATION LIMITED

裕承科金有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 279)

**PROPOSALS FOR REFRESHMENT OF GENERAL MANDATES TO
ISSUE AND REPURCHASE SHARES;
RE-ELECTION OF RETIRING DIRECTORS;
AND
NOTICE OF ANNUAL GENERAL MEETING**

A notice convening an annual general meeting of Arta TechFin Corporation Limited to be held at Meeting Room S228, 2/F (Phase 1), Hong Kong Convention and Exhibition Centre (Harbour Road Entrance), 1 Expo Drive, Wanchai, Hong Kong on Thursday, 28 September 2023 at 5:00 p.m. (the “AGM”) is set out on pages 14 to 18 of this circular.

Whether or not you are able to attend the AGM in person, you are requested to complete and return the accompanying form of proxy in accordance with the instructions printed thereon to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Secretaries Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but not less than 48 hours before the time appointed for the holding of the AGM. Completion and return of a form of proxy will not preclude you from attending and voting at the AGM or any adjourned meetings in person if you so wish.

6 September 2023

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
APPENDIX I - EXPLANATORY STATEMENT FOR THE REPURCHASE MANDATE	6
APPENDIX II - DETAILS OF DIRECTORS PROPOSED FOR RE-ELECTION	10
NOTICE OF ANNUAL GENERAL MEETING	14

DEFINITIONS

In this circular, the following expressions have the following meanings, unless the context requires otherwise:

“Annual General Meeting” or “AGM”	the annual general meeting of the Company to be held at Meeting Room S228, 2/F (Phase 1), Hong Kong Convention and Exhibition Centre (Harbour Road Entrance), 1 Expo Drive, Wanchai, Hong Kong on Thursday, 28 September 2023 at 5:00 p.m., the notice of which is set out on pages 14 to 18 of this circular
“Articles”	the Articles of Association of the Company
“Auditor”	at any time means the auditor of the Company
“Board”	the board of Directors
“close associate(s)”	the meaning ascribed thereto under the Listing Rules
“Company”	Arta TechFin Corporation Limited, a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the main board of the Stock Exchange (Stock Code: 279)
“core connected person(s)”	the meaning ascribed thereto under the Listing Rules
“Directors”	the directors of the Company
“Extension Mandate”	the extension of Issue Mandate by a separate resolution to include the Shares repurchased under the Repurchase Mandate up to 10% of the total number of the issued Shares of the Company as at the date of the AGM
“General Mandates”	the Issue Mandate and the Extension Mandate
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Issue Mandate”	a general mandate proposed to be granted to the Directors to exercise all the powers of the Company to allot, issue and deal with Shares in the manner as set out herein

DEFINITIONS

“Latest Practicable Date”	31 August 2023, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Repurchase Mandate”	a general mandate proposed to be granted to the Directors to exercise all the powers of the Company to repurchase Shares in the manner as set out herein
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	the ordinary share(s) of HK\$0.01 each in the issued share capital of the Company
“Shareholder(s)”	holder(s) of Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“substantial shareholder(s)”	the meaning ascribed thereto under the Listing Rules
“Takeovers Code”	the Hong Kong Code on Takeovers and Mergers
“%” or “per cent.”	percentage or per centum

LETTER FROM THE BOARD



ARTA TECHFIN CORPORATION LIMITED

裕承科金有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 279)

Executive Directors:

Mr. Lau Fu Wing, Eddie (*Chief Executive Officer*)

Ms. Li Chuchu, Tracy (*Deputy Chief Financial Officer*)

Ms. Yeung Shuet Fan Pamela (*Chief Financial Officer*)

Non-executive Directors:

Dr. Cheng Chi-Kong, Adrian SBS, JP (*Chairman*)

Mr. Han Kam Leung, Michael

Independent Non-executive Directors:

Ms. Ling Kit Sum Imma

Mr. Lo Chun Yu Toby

Dr. Tam Lai Fan Gloria

Registered Office:

Cricket Square, Hutchins Drive

P.O. Box 2681

Grand Cayman

KY1-1111

Cayman Islands

Principal Place of Business

in Hong Kong:

Units 1-2, level 9

K11 ATELIER King's Road

728 King's Road

Quarry Bay, Hong Kong

6 September 2023

To the Shareholders

Dear Sir or Madam,

**PROPOSALS FOR REFRESHMENT OF GENERAL MANDATES TO
ISSUE AND REPURCHASE SHARES;
RE-ELECTION OF RETIRING DIRECTORS;
AND
NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

The purpose of this circular is to provide you with all the information reasonably necessary to enable you to make an informed decision on whether to vote for or against the proposed resolutions at the AGM, which include, *inter alia*, the grant of the Issuance Mandate and Repurchase Mandate, the extension of the Issue Mandate, the re-election of retiring Directors, and to send you the notice of the AGM.

LETTER FROM THE BOARD

REFRESHMENT OF GENERAL MANDATES AND REPURCHASE MANDATE

The existing general mandates to issue and repurchase Shares will expire at the conclusion of the forthcoming AGM. The Directors intend to put forward to the Shareholders ordinary resolutions at the AGM to renew the general mandates so as to give Directors general authority:

- (i) to allot, issue and otherwise deal with new Shares with not exceeding 20% of the total number of the issued shares of the Company as at the date of passing the proposed resolution at the AGM; and
- (ii) to repurchase Shares not exceeding 10% of the total number of the issued shares of the Company as at the date of passing the proposed resolution at the AGM.

As at the Latest Practicable Date, the total number of issued Shares was 19,143,179,880. Assuming that no further Shares are repurchased or issued between the Latest Practicable Date and the date of the AGM, subject to the approval of the Issue Mandate by the Shareholders, the Company would be allowed to issue a maximum of 3,828,635,976 Shares under the proposed Issue Mandate.

A separate ordinary resolution will also be proposed at the AGM to add those Shares repurchased by the Company pursuant to the Repurchase Mandate to the Issue Mandate.

An explanatory statement as required under the Listing Rules to provide the requisite information in relation to the Repurchase Mandate is set out in Appendix I of this circular.

RE-ELECTION OF RETIRING DIRECTORS

As at the Latest Practicable Date, there were three Executive Directors, namely Mr. Lau Fu Wing, Eddie (“**Mr. Lau**”), Ms. Li Chuchu, Tracy (“**Ms. Li**”) and Ms. Yeung Shuet Fan Pamela (“**Ms. Yeung**”); two Non-executive Directors, namely Dr. Cheng Chi-Kong, Adrian *SBS, JP* (“**Dr. Cheng**”) and Mr. Han Kam Leung, Michael (“**Mr. Han**”); and three Independent Non-executive Directors, namely Ms. Ling Kit Sum Imma (“**Ms. Ling**”), Mr. Lo Chun Yu Toby (“**Mr. Lo**”) and Dr. Tam Lai Fan Gloria (“**Dr. Tam**”).

Pursuant to Article 112 of the Articles, Ms. Li, Mr. Han, Dr. Tam and Ms. Yeung will retire from office. Among them, Ms. Li, Mr. Han and Dr. Tam offer themselves for re-election at the AGM while Ms. Yeung will not seek for re-election at the AGM and will retire as an Executive Director after the conclusion of the AGM.

Details of the Directors proposed for re-election at the AGM are set out in Appendix II of this circular.

LETTER FROM THE BOARD

NOTICE OF ANNUAL GENERAL MEETING

Notice of AGM is set out on pages 14 to 18 of this circular. A form of proxy for use at the AGM is enclosed. Whether or not you are able to attend the AGM in person, you should complete and return the accompanying form of proxy in accordance with the instructions printed thereon to the Company's branch share registrar and transfer office in Hong Kong, Tricor Secretaries Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but not less than 48 hours before the time appointed for the holding of the AGM. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof, should you so wish.

As at the Latest Practicable Date and insofar as the Directors are aware and having made all reasonable enquiries, no Shareholder is required to abstain from voting on any resolution to be proposed at the Annual General Meeting.

Pursuant to Rule 13.39(4) of the Listing Rules, all votes at the AGM will be taken by way of poll except where the chairman of the AGM, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands, and the Company will announce the results of the poll in the manner set out in Rule 13.39(5) of the Listing Rules.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

RECOMMENDATION

The Directors are of the opinion that the proposals for refreshment of General Mandates to issue and repurchase shares and re-election of retiring directors are all in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends you to vote in favour of all the resolutions to be proposed at the AGM.

Your attention is also drawn to the additional information set out in the appendices to this circular.

By Order of the Board
Arta TechFin Corporation Limited
Lau Fu Wing, Eddie
Chief Executive Officer

This section includes an explanatory statement required by the Listing Rules to be presented to Shareholders concerning the Repurchase Mandate.

1. LISTING RULES FOR REPURCHASES OF SHARES

The Listing Rules permit companies with a primary listing on the Stock Exchange to repurchase their shares on the Stock Exchange subject to certain restrictions.

The Listing Rules provide that all proposed repurchases of shares by a company with a primary listing on the Stock Exchange must be approved by shareholders in advance by an ordinary resolution, either by way of a general mandate or by a specific approval of a particular transaction and that the shares to be repurchased must be fully paid up.

2. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 19,143,179,880 Shares.

Subject to the passing of the relevant ordinary resolutions to approve the Issue Mandate and the Repurchase Mandate and on the basis that no further Shares are issued or repurchased between the Latest Practicable Date and the date of the AGM, the Company would be allowed under the Repurchase Mandate to repurchase a maximum of 1,914,317,988 Shares representing not more than 10% of the issued Shares of the Company at the Latest Practicable Date.

3. REASONS FOR REPURCHASES

The Directors believe that it is in the best interests of the Company and the Shareholders to have a general authority from the Shareholders to enable the Directors to repurchase Shares on the market. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value and/or earnings per Share of the Company and will only be made when the Directors believe that such repurchases will benefit the Company and the Shareholders.

4. FUNDING OF REPURCHASES

Any repurchase will be made out of funds which are legally available for the purpose in accordance with the Memorandum and Articles of Association of the Company, the Listing Rules and the applicable laws and regulations of the Cayman Islands, including profits of the Company or out of the proceeds of a fresh issue of the Shares made for the purpose of the repurchase.

In the event that the Repurchase Mandate was to be exercised in full at any time during the proposed period within which the Repurchase Mandate may be exercised, there might be a material adverse impact on the working capital and/or gearing position of the Company as compared with the position of the Company as disclosed in the audited financial statements contained in the annual report of the Company for the year ended 31 March 2023. However, the Directors do not propose to exercise the Repurchase Mandate to such an extent as would, in the circumstances, have a material adverse effect on the working capital and/or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company.

5. SHARE PRICES

The highest and lowest prices at which the Shares were traded on the Stock Exchange in each of the previous twelve months before the Latest Practicable Date are as follows:

	Per Share	
	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
August 2022	0.172	0.140
September 2022	0.148	0.114
October 2022	0.146	0.106
November 2022	0.134	0.108
December 2022	0.125	0.105
January 2023	0.118	0.106
February 2023	0.115	0.103
March 2023	0.125	0.091
April 2023	0.118	0.100
May 2023	0.114	0.091
June 2023	0.109	0.090
July 2023	0.105	0.086
August 2023 (up to the Latest Practicable Date)	0.092	0.072

6. UNDERTAKING OF THE DIRECTORS

The Directors have undertaken to the Stock Exchange to exercise the powers of the Company to make repurchases under the Repurchase Mandate in accordance with the Listing Rules, the applicable laws of the Cayman Islands and in accordance with the Articles.

None of the Directors nor, to the best of their knowledge and belief having made all reasonable enquiries, any of their close associates has any present intention to sell Shares to the Company if the Repurchase Mandate is approved by the Shareholders.

No core connected persons of the Company has notified the Company that they have a present intention to sell Shares to the Company, or have undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

7. EFFECT OF THE TAKEOVERS CODE

Repurchase of Shares may result in an increase in the proportionate interests of a Shareholder in the voting rights of the Company and such increase will be treated as an acquisition of voting rights for the purpose of the Takeovers Code. As a result, a Shareholder or a group of Shareholders acting in concert, depending on the level of increase of the Shareholder's interest, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, Dr. Cheng Chi-Kong, Adrian *SBS, JP* ("**Dr. Cheng**") is the ultimate beneficial owner of Radiant Alliance Limited which holds 14,011,317,504 Shares, representing approximately 73.19% of the total issued share of the Company. In the event the Directors exercised in full the power to repurchase Shares pursuant to the Repurchase Mandate which is to be approved by the Shareholders, then (if the present shareholding remains the same) the deemed interest of Dr. Cheng Chi-Kong, Adrian *SBS, JP* would be increased to approximately 81.32% of the total issued Shares of the Company. The Directors are not aware of such an increase would give rise to an obligation to make a mandatory offer under the Takeovers Code if the Repurchase Mandate was to be exercised in full.

Assuming that there is no further issue of Shares between the Latest Practicable Date and the date of Share repurchase, the exercise of the Repurchase Mandate whether in whole or in part will result in less than 25% of the total number of Shares in issue being held by the public as required by Rule 8.08 of the Listing Rules. The Directors, however, have no present intention to exercise the power to repurchase Shares pursuant to the Repurchase Mandate to such an extent.

8. SHARE REPURCHASE MADE BY THE COMPANY

The Company has not repurchased any Shares (whether on the Stock Exchange or otherwise) during the six months preceding the Latest Practicable Date.

The followings are the particulars of the Directors proposed for re-election at the Annual General Meeting.

EXECUTIVE DIRECTOR

Ms. Li Chuchu, Tracy (“Ms. Li”), aged 33, is an Executive Director of the Company. She was appointed as the Deputy Chief Financial Officer of the Company in April 2023. She is currently a director of certain private limited companies in which Dr. Cheng Chi-Kong, Adrian SBS, JP and his associates ultimately own majority interests, and regarding which Ms. Li holds supervisory or consulting roles and is responsible for investment and financial management. Ms. Li has extensive experience in private equity investment, post-investment management, financial advisory and risk management. Before joining Avantua Capital Management Limited in May 2020, Ms. Li was an investment director at a private investment firm from December 2017 to April 2020. From April 2015 to December 2017, Ms. Li was a manager in advisory services of a global advisory firm and was responsible for due diligence, regulatory compliance, risk management and corporate governance. From September 2012 to March 2015, she worked as an assistant manager in audit services of an international accounting firm. Ms. Li earned a Bachelor of Business Administration in Professional Accountancy from The Chinese University of Hong Kong in 2012. She is a fellow member of Hong Kong Institute of Certified Public Accountants.

Ms. Li has entered into a letter of appointment with the Company in relation to her appointment as an Executive Director for a term of one year commencing on 29 October 2022 which is terminable by a three months’ notice in writing served by either party on the other without payment of compensation. Ms. Li also entered into an employment contract with the Company and is entitled to receive a monthly basic salary of HK\$196,065 and discretionary bonus for her appointment as the Deputy Chief Financial Officer, as determined by the Board with reference to her experience, duties and responsibilities of her positions and the prevailing market conditions.

Ms. Li did not hold directorship in any other listed public companies in the last three years. Save as disclosed, Ms. Li does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. As at the Latest Practicable Date, Ms. Li does not have any interest in the Shares within the meaning of Part XV of the SFO.

Save as disclosed herein, there is no information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules relating to the re-election of Ms. Li and there is no other matter that needs to be brought to the attention of the Shareholders.

NON-EXECUTIVE DIRECTOR

Mr. Han Kam Leung, Michael (“Mr. Han”), aged 52, is a Non-executive Director, a member of the Audit Committee of the Company. He is a veteran in the insurance industry in Hong Kong and mainland China with over 27 years of experience. Mr. Han has diverse experience in corporate compliance management and legal regulation of insurance industry in Hong Kong and mainland China. He is the chief executive officer (re-designated from deputy chief executive officer in July 2022) of Concord Insurance Company Limited (“Concord”), in which Dr. Cheng Chi-Kong, Adrian SBS, JP and his associates ultimately own majority interests. Before joining Concord, Mr. Han was the responsible officer in certain wholly-owned subsidiaries of the Company from March 2021 to September 2021. From 2006 to 2018, Mr. Han worked in Hong Kong and Shanghai with Mitsui Sumitomo Insurance Group and the head office of All Trust Insurance China Company as senior director and general manager respectively, taking up key management responsibilities on company strategic planning and business development. Mr. Han holds a Bachelor Degree in Business Administration Marketing from University of Sunderland.

Mr. Han has entered into a letter of appointment with the Company for a term of one year commencing on 29 October 2022 which is terminable by a three months’ notice in writing served by either party on the other without payment of compensation. Mr. Han is entitled to an annual emolument of HK\$100,000 for his appointment as a Non-executive Director, as determined by the Board with reference to his experience, duties and responsibilities of his positions and the prevailing market conditions.

Mr. Han did not hold directorship in any other listed public companies in the last three years. Save as disclosed, Mr. Han does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. As at the Latest Practicable Date, Mr. Han does not have any interest in the Shares within the meaning of Part XV of the SFO.

Save as disclosed herein, there is no information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules relating to the re-election of Mr. Han and there is no other matter that needs to be brought to the attention of the Shareholders.

INDEPENDENT NON-EXECUTIVE DIRECTOR

Dr. Tam Lai Fan Gloria (“Dr. Tam”), aged 66, is an Independent Non-executive Director, the chairlady of the Remuneration Committee and a member of the Audit Committee and the Nomination Committee of the Company. Dr. Tam finished her undergraduate medical training at The University of Hong Kong in 1982 and joined Hong Kong Government’s medical and health service in 1985. She completed her Master of Medicine (Public Health) at National University of Singapore in 1992. From 1997 to 2003, Dr. Tam was Assistant Director of Health responsible for both food safety and food animal zoonosis. She received risk communication training in Harvard’s School of Public Health in 2004 and was elected a Fellow of UK’s Faculty of Public Health in 2007. In the same year, she was appointed as Deputy Director of Health, supervising over 5,000 staff and deputising Director of Health in all departmental matters except dental and disease control and prevention. She underwent Wharton Business School’s Advanced Management Program in 2010 and was Valedictorian of Singapore College of Civil Service’s flagship course, Leadership in Governance course in 2011. In mid-June 2012, Dr. Tam was promoted to become Controller for Food Safety of Food and Environmental Hygiene Department. Dr. Tam retired from Hong Kong civil service in June 2017. She is currently member of Li Po Chun United World College of Hong Kong’s Board, Singapore International School’s Board of Governors and Tung Wah College’s Council. Her other positions include Technical Advisor of Hong Kong’s Smart City Consortium; Consultant of Department of Veterinary Regulation and Biosecurity Policy of Hong Kong Jockey Club; and Adviser of Workers’ Medical Clinics, Hong Kong Federation of Trade Unions. Since 2018, she has been a member of Hunan Provincial Committee of Chinese People’s Political Consultative Conference and an expert of United Nations’ Food and Agriculture Organization and World Health Organization Joint Expert Meeting on Microbiological Risk Assessment. Dr. Tam is also a member of Hong Kong Coalition since its set up in 2020. Dr. Tam was appointed as an independent non-executive director of OrbusNeich Medical Group Holdings Limited (stock code: 6929), which is a company listed on the Main Board of the Stock Exchange in December 2022. She also served as an independent non-executive director of Zhaoke Ophthalmology Limited (stock code: 6622), which is a company listed on the Main Board of the Stock Exchange, from April 2021 to April 2022. She is now a consultant of Mainland’s China General Chamber of Commerce and also the local Kowloon Chamber of Commerce.

Dr. Tam has entered into a letter of appointment with the Company for a term of one year commencing on 29 October 2022 which is terminable by a two months' notice in writing served by either party on the other without payment of compensation. Dr. Tam is entitled to an annual emolument of HK\$200,000 for her appointment as an Independent Non-executive Director, as determined by the Board with reference to her experience, duties and responsibilities of her positions and the prevailing market conditions.

Save as disclosed, Dr. Tam did not hold directorship in any other listed public companies in the last three years. Dr. Tam is not connected with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company. Dr. Tam does not have any interests in the Shares which is required to be disclosed under Part XV of the SFO.

Save as disclosed herein, there is no information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules relating to the re-election of Dr. Tam and there is no other matter that needs to be brought to the attention of the Shareholders.

NOTICE OF ANNUAL GENERAL MEETING



ARTA TECHFIN CORPORATION LIMITED

裕承科金有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 279)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that an annual general meeting of Arta TechFin Corporation Limited (the “**Company**”) will be held at Meeting Room S228, 2/F (Phase 1), Hong Kong Convention and Exhibition Centre (Harbour Road Entrance), 1 Expo Drive, Wanchai, Hong Kong on Thursday, 28 September 2023 at 5:00 p.m. (the “**AGM**”) for the following purposes:

AS ORDINARY BUSINESS

1. To consider and adopt the audited Financial Statements and the Reports of the Directors and the Independent Auditor of the Company for the year ended 31 March 2023.
2. To re-elect Directors and authorise the board (the “**Board**”) of directors (the “**Directors**”) of the Company to fix their remuneration, including:
 - (a) To re-elect Ms. Li Chuchu, Tracy as an executive Director.
 - (b) To re-elect Mr. Han Kam Leung, Michael as a non-executive Director.
 - (c) To re-elect Dr. Tam Lai Fan Gloria as an independent non-executive Director.
 - (d) To authorise the Board to fix the Directors’ remuneration.
3. To re-appoint Crowe (HK) CPA Limited as the auditor of the Company and to authorise the Board of Directors to fix their remuneration.

NOTICE OF ANNUAL GENERAL MEETING

AS SPECIAL BUSINESS

To consider and, if thought fit, pass the following resolutions as ordinary resolutions:

4. **“THAT:**

- (i) subject to paragraph (iii) below pursuant to the Listing Rules, the exercise by the Directors of the Company during the Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue and deal with additional shares in the capital of the Company and to make or grant offers, agreements and options, including bonds, warrants and debentures convertible into shares of the Company, which would or might require the exercise of such powers to issue shares of the Company be and is hereby generally and unconditionally approved;
- (ii) the approval in paragraph (i) above shall authorise the Directors of the Company during the Relevant Period to allot, issue and deal with additional shares in the share capital of the Company and to make or grant offers, agreements and options, including bonds, warrants and debentures convertible into shares of the Company which would or might require the exercise of such powers after the end of the Relevant Period;
- (iii) the total number of shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) and issued by the Company pursuant to the approval granted in paragraph (i) above, otherwise than pursuant to (a) a Rights Issue (as hereinafter defined); (b) the exercise of any conversion rights attaching to any securities which are convertible into shares of the Company; (c) the exercise of the rights under any option scheme or similar arrangement for the time being adopted for the grantor issue to Directors and/or employees of the Company and/or any of its subsidiaries and/or eligible participants as defined under such option scheme of options to subscribe for, or rights to acquire, shares of the Company; or (d) any issue of shares as scrip dividends or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company pursuant to the applicable law or the Articles of Association of the Company from time to time, shall not exceed 20% of the total number of issued shares of the Company as at the date of passing of this resolution, provided that if any subsequent consolidation or subdivision of shares of the Company is effected, the maximum number of shares of the Company that may be issued pursuant to the approval in paragraph (i) above as a percentage of the total number of issued shares of the Company at the date immediately before and after such consolidation or subdivision shall be the same and such maximum number of shares of the Company shall be adjusted accordingly, and the approval granted in paragraph (i) shall be limited accordingly; and

NOTICE OF ANNUAL GENERAL MEETING

- (iv) for the purposes of this Resolution:

“Relevant Period” means the period from the passing of this Resolution until whichever is the earliest of:

- (a) the conclusion of the next annual general meeting of the Company;
- (b) the expiration of the period within which the next annual general meeting of the Company is required by the applicable law or the Articles of Association of the Company to be held; and
- (c) the revocation or variation of the authority given under the resolution by an ordinary resolution of the shareholders of the Company in general meeting.

“Rights Issue” means an offer of shares open for a period fixed by the Directors of the Company to holders of shares whose names appear on the register of members of the Company on a fixed record date in proportion to their then holdings of such shares (subject to such exclusions or other arrangements as the Directors of the Company may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory applicable to the Company).”

5. **“THAT:**

- (i) subject to paragraph (iii) below, the exercise by the Directors of the Company during the Relevant Period (as hereinafter defined) of all powers of the Company to repurchase issued shares or any other rights to subscribe shares in the capital of the Company in each case on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or on any other stock exchange on which the securities of the Company may be listed and which is recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose, subject to and in accordance with all applicable laws and/or the requirements of the Stock Exchange or of any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved;
- (ii) the approval in paragraph (i) above shall authorise the Directors of the Company on behalf of the Company during the Relevant Period to procure the Company to repurchase its shares at a price determined by the Directors of the Company;

NOTICE OF ANNUAL GENERAL MEETING

(iii) the total number of shares which may be repurchased by the Company pursuant to the approval in paragraph (i) above shall not exceed 10% of the total number of issued shares of the Company as at the date of the passing of this resolution, provided that if any subsequent consolidation or subdivision of shares of the Company is effected, the maximum number of shares of the Company that may be repurchased pursuant to the approval in paragraph (i) of this resolution as a percentage of the total number of issued shares of the Company at the date immediately before and after such consolidation or subdivision shall be the same and such maximum number of shares of the Company shall be adjusted accordingly, and the authority granted pursuant to paragraph (i) of this resolution shall be limited accordingly; and

(iv) for the purposes of this Resolution:

“Relevant Period” means the period from the passing of this Resolution until whichever is the earliest of:

- (a) the conclusion of the next annual general meeting of the Company;
- (b) the expiration of the period within which the next annual general meeting of the Company is required by any applicable law or the Articles of Association of the Company to be held; and
- (c) the revocation or variation of the authority given under the resolution by an ordinary resolution of the shareholders of the Company in general meeting.”

6. “**THAT** conditional on the passing of the Resolutions numbered 4 and 5 set out in the notice of the annual general meeting at which this Resolution is considered, the general mandate granted to the Directors of the Company and for the time being in force to exercise the powers of the Company to allot, issue and deal with new shares pursuant to the Resolution numbered 4 set out in the said notice be and is hereby extended by the addition to the total number of the shares of the Company, which may be allotted or agreed conditionally or unconditionally to be allotted by the Directors of the Company pursuant to such general mandate of an amount representing the total number of the shares of the Company repurchased by the Company under the authority granted pursuant to the said Resolution numbered 5.”

By Order of the Board
Arta TechFin Corporation Limited
Lau Fu Wing, Eddie
Chief Executive Officer

Hong Kong, 6 September 2023

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. To be valid, the instrument appointing a proxy must be in writing under the hand of the appointor or of his attorney authorised in writing or if the appointor is a corporation, either under seal or under the hand of an officer or attorney duly authorised.
2. Any member of the Company entitled to attend and vote at the meeting shall be entitled to appoint another person as his proxy to attend and vote instead of him. On a poll votes may be given either personally or by proxy. A proxy need not be a member of the Company. A member may appoint more than one proxy to attend on the same occasion.
3. The instrument appointing a proxy and the power of attorney or other authority, if any, under which it is signed or a notorially certified copy of that power or authority must be deposited at the Company's branch share registrar and transfer office in Hong Kong, Tricor Secretaries Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time for holding the meeting or the adjourned meeting or poll (as the case may be) at which the person named in such instrument proposes to vote, and in default the instrument of proxy shall not be treated as valid.
4. The register of members of the Company will be closed from Monday, 25 September 2023 to Thursday, 28 September 2023, both days inclusive, in order to determine the eligibility of shareholders of the Company to attend and vote the above meeting, during which period no share transfers will be registered. To be eligible to attend and vote at the above meeting, all properly completed transfer forms accompanied by the relevant share certificates must be lodged for registration with the Company's branch share registrar and transfer office in Hong Kong, Tricor Secretaries Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Friday, 22 September 2023.
5. Where there are joint registered holders of any share, any one of such persons may vote at the meeting, either personally or by proxy, in respect of such share as if he were solely entitled thereto; but if more than one of such joint holders be present at the meeting personally or by proxy, that one of the said persons so present whose name stands first on the register of members in respect of such share shall alone be entitled to vote in respect thereof.
6. A form of proxy for use at the AGM is enclosed herewith.
7. If a tropical cyclone warning signal no. 8 or above is in force in Hong Kong at any time between 1:00 p.m. to 5:00 p.m. on Thursday, 28 September 2023, the Annual General Meeting will not be held on that day but will be automatically postponed. The Company will publish an announcement on its website and on the website of the Stock Exchange to notify members of the Company of the date, time and location of the rescheduled meeting.
8. The translation into Chinese language of this notice is for reference only. In case of any inconsistency, the English version shall prevail.
9. As at the date of this notice, the Board of the Company comprises Dr. Cheng Chi-Kong, Adrian *SBS, JP* (Chairman) and Mr. Han Kam Leung, Michael as Non-executive Directors, Mr. Lau Fu Wing, Eddie (Chief Executive Officer), Ms. Li Chuchu, Tracy (Deputy Chief Financial Officer) and Ms. Yeung Shuet Fan Pamela (Chief Financial Officer) as Executive Directors, and Ms. Ling Kit Sum Imma, Mr. Lo Chun Yu Toby and Dr. Tam Lai Fan Gloria as Independent Non-executive Directors.